Multiple Sclerosis Drug Price Increases Probed By House Oversight Panel Democrats

Reps. Cummings and Welch contact seven manufacturers of multiple sclerosis drugs with inquiries about persistent and significant annual price increases. The members suggest some firms are boosting prices in "lockstep."

More from Pricing Debate

More from Market Access